Treatment of Basal Cell Carcinoma with Intralesional Interferon Alpha-2b | Zendy

M.F. HEALSMITH | Zendy; J. BerthJones | Zendy; Ashley A. Fletcher | Zendy; R.A.C. GRAHAM-BROWN | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Basal Cell Carcinoma with Intralesional Interferon Alpha-2b

Author(s) -

M.F. HEALSMITH,

J. BerthJones,

Ashley A. Fletcher,

R.A.C. GRAHAM-BROWN

Publication year - 1991

Publication title -

journal of the royal society of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.38

H-Index - 81

eISSN - 1758-1095

pISSN - 0141-0768

DOI - 10.1177/014107689108400907

Subject(s) - alpha interferon , medicine , malignancy , basal cell carcinoma , basal (medicine) , interferon , pathology , alpha (finance) , interferon alfa , carcinoma , basal cell , surgery , immunology , construct validity , insulin , patient satisfaction

We report a series of 11 basal cell carcinomas of various types treated with nine intra-lesional injections of 1.5 million units of interferon alpha-2b. The diagnosis was confirmed histologically in each case. After 3 months' follow-up six tumours had resolved both clinically and histologically. In three cases the tumour size was reduced. One tumour grew larger. Side effects were well tolerated except by one subject who was withdrawn. Those cases which responded have now been followed-up for between 12 and 26 months with no clinical or histological evidence of tumour recurrence. This is the longest period of follow-up so far reported for this novel treatment. The results are encouraging and, if maintained in future series, may indicate a useful role for interferon alpha in the management of this common cutaneous malignancy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research